Replies to post #408468 on Anavex Life Sciences Corp (AVXL)

[BAR123]

So what you are saying is that we need the full data set from the company for the Alzheimer’s p2/3 trial for us to reach fair value? If that is what you are suggesting then our ability to not reach fair value is truly based on the realization that the street does not trust Dr Missling when he says that we met all primary and secondary endpoints. If Biogen published the same press release that we did in early December they would have gone up tremendously. But since Wall Street has no history with Missling the company takes a hit for having a rookie ceo. Also lets not use the market down turn as a defense. If we had the right data the market would not care. We would be up. Maybe not to a $7B market cap but certainly $3-$5B.